U.S. Global Investors (USGI)’s Regeneron Pharmaceuticals REGN Stock Holding History

U.S. Global Investors (USGI)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,430	Closed	-$977K	–	197
2016 Q3	$977K	Sell	2,430 -350	-13%	-$140K	0.46%	70
2016 Q2	$971K	Buy	2,780 +647	+30%	+$249K	0.53%	73
2016 Q1	$769K	Sell	2,133 -1,467	-41%	-$605K	0.41%	85
2015 Q4	$1.95M	Buy	+3,600	New	+$1.95M	1.02%	26
2014 Q1	–	Sell	-900	Closed	-$248K	–	361
2013 Q4	$248K	Buy	+900	New	+$259K	0.04%	223

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

U.S. Global Investors (USGI)'s REGN Position: Q4 2016 in Review

U.S. Global Investors (USGI) sold out of Regeneron Pharmaceuticals (REGN) in Q4 2016, closing a stake of 2,430 shares — an estimated $977K sold.

U.S. Global Investors (USGI) first reported a position in REGN in Q4 2013 and held it in 5 quarters. The position peaked at $1.95M in Q4 2015. 576 funds tracked by Wall St. Rank hold REGN as of Q4 2016.

U.S. Global Investors (USGI) reported no remaining Regeneron Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
U.S. Global Investors (USGI) sold 2,430 Regeneron Pharmaceuticals shares in Q4 2016, an estimated $977K.
U.S. Global Investors (USGI) first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 5 quarters.
U.S. Global Investors (USGI)'s Regeneron Pharmaceuticals position peaked at $1.95M in Q4 2015.
576 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2016.

Based on U.S. Global Investors (USGI)'s 13F filing for Q4 2016, filed 14 Feb 2017.